After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...
It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its ...
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an ...
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...
This article originally appeared on Mississippi Clarion Ledger: Vote for Jackson Metro Student of the Week Nov. 3-9 ...
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
Hsiao is on the board of directors for the Hidradenitis Suppurativa Foundation and has declared relationships with AbbVie, ...
Sale prices have skyrocketed in parts of the Capital Region over the past five years, pushing these local areas into the ...
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% ...
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by Royal Bank of Canada from ...
A new immune structure found in liver tumors could improve treatment for liver cancer patients. These structures are linked ...
On Thursday, Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $838.2 which represents a decrease of $-84.59 or -9.17% from the prior close of $922.79. The stock opened at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback